1. QUESTIONS
============

In adult patients with inoperable locally advanced or metastatic soft-tissue sarcoma ([sts]{.smallcaps}), do combination chemotherapy regimens containing ifosfamide have an advantage in terms of response rate, time to progression, or survival, as compared with similar regimens without ifosfamide when used as first-line therapy?

What are the adverse effects and effects on quality of life of ifosfamide-containing combination chemotherapy as compared with similar regimens without ifosfamide?

2. CHOICE OF TOPIC AND RATIONALE
================================

The prognosis for patients with inoperable or meta-static [sts]{.smallcaps} remains grim. Although surgical resection of pulmonary metastases may be curative in 15%--30% of patients with isolated, slow-growing metastases [@b1-co14_4p144],[@b2-co14_4p144], most patients receive chemotherapy for palliative purposes.

Ifosfamide has documented activity in patients who have received prior treatment with, or who have progressed on, doxorubicin [@b3-co14_4p144]--[@b6-co14_4p144].A number of studies have suggested a schedule and dose--response relationship for ifosfamide in metastatic [sts]{.smallcaps} [@b6-co14_4p144]--[@b8-co14_4p144]. The drug has also been assessed in combination with other drugs such as doxorubicin and dacarbazine ([dtic]{.smallcaps}) [@b6-co14_4p144],[@b9-co14_4p144],[@b10-co14_4p144]. The results of such studies have led some authors to suggest that polychemotherapy with "appropriate doses" of ifosfamide and doxorubicin may represent the "most effective systemic treatment" in this population.

Given the limited effective therapeutic options available to patients with metastatic [sts]{.smallcaps}, the Sarcoma [dsg]{.smallcaps} felt that a need existed to more specifically evaluate the potential benefits of ifosfamide-containing combination chemotherapy in that setting.

3. METHODS
==========

3.1 Guideline Development
-------------------------

The present practice guideline was developed by the Sarcoma Disease Site Group ([dsg]{.smallcaps}) of Cancer Care Ontario's Program in Evidence-based Care ([pebc]{.smallcaps}), using the methods of the practice guidelines development cycle [@b11-co14_4p144]. This practice guideline is a convenient and up-to-date source of the best available evidence on ifosfamide-based combination chemotherapy for patients with inoperable locally advanced or metastatic [sts]{.smallcaps}. The body of evidence in this report is composed primarily of data from mature randomized controlled trials ([rct]{.smallcaps}s). That evidence forms the basis of a clinical practice guideline developed by the Sarcoma [dsg]{.smallcaps}. The systematic review (which is under consideration for publication elsewhere) and the companion practice guideline are intended to promote evidence-based practice in Ontario, Canada. The evidence was selected and reviewed by one member of the Sarcoma [dsg]{.smallcaps} and by methodologists. Members of the Sarcoma [dsg]{.smallcaps} disclosed information on potential conflicts of interest. No conflicts were declared. The [pebc]{.smallcaps} is editorially independent of Cancer Care Ontario and the Ontario Ministry of Health and Long-Term Care.

External review is obtained for all practice guideline reports through a mailed survey of Ontario practitioners. The survey consists of items that address the quality of the draft practice guideline report and recommendations, and that ask whether the recommendations should serve as a practice guideline. Final approval of the practice guideline report is obtained from the [pebc]{.smallcaps}'s Report Approval Panel ([rap]{.smallcaps}).

3.2 Literature Search Strategy
------------------------------

The [medline]{.smallcaps} (1966 to July 2005), [embase]{.smallcaps} (1980 to July 2005), and Cochrane Library (2004, Issue 3) databases were systematically searched for eligible randomized controlled phase [ii]{.smallcaps} and [iii]{.smallcaps} trials, practice guidelines, systematic reviews, and meta-analyses. In addition, conference proceedings of the American Society of Clinical Oncology (1997 to Spring 2005) were searched for abstracts of relevant trials.

4. LITERATURE SEARCH RESULTS
============================

The literature search identified three randomized trials phase [iii]{.smallcaps}[@b9-co14_4p144],[@b10-co14_4p144],[@b12-co14_4p144] and twenty-three single-arm phase trials [ii]{.smallcaps}[@b6-co14_4p144],[@b13-co14_4p144]--[@b34-co14_4p144] that met the inclusion criteria for this systematic review of the evidence.

All three [rct]{.smallcaps}s [@b9-co14_4p144],[@b10-co14_4p144],[@b12-co14_4p144] and sixteen of the phase [ii]{.smallcaps} trials [@b6-co14_4p144],[@b14-co14_4p144]--[@b28-co14_4p144] used ifosfamide with an anthracycline (doxorubicin or epirubicin). The remaining seven phase studies [ii]{.smallcaps}[@b13-co14_4p144],[@b29-co14_4p144]--[@b34-co14_4p144] used ifosfamide in combinations that did not include an anthracycline. Two of s the [rct]{.smallcaps} [@b10-co14_4p144],[@b12-co14_4p144] reported that the addition of ifosfamide to an anthracycline regimen (either doxorubicin, or doxorubicin and [dtic]{.smallcaps}) significantly improved the response rate (34%, *p* = 0.03, and 32%, *p* \< 0.005, respectively). The by Antman et al. [rct]{.smallcaps}[@b12-co14_4p144] also reported a significant improvement in overall survival (*p* = 0.04) for patients who received doxorubicin and [dtic]{.smallcaps} as compared with patients who received [maid]{.smallcaps} (mesna, doxorubicin, ifosfamide, and [dtic]{.smallcaps}). The reason for that finding cannot be discerned from the trial, but histologic differences in the trial population could possibly have resulted in subtle imbalances in the treatment arms.

All three [rct]{.smallcaps}s reported higher rates of adverse events in the regimens that contained ifosfamide. Two of the trials reported that grades 3 and 4 adverse events were much higher in the ifosfamide arm [@b10-co14_4p144],[@b12-co14_4p144]. Both trials reported a total of 11 toxic deaths, plus increased hematologic toxicity \[myelosuppression (80%) and leucopenia (86%)\].

Although the [dsg]{.smallcaps} identified and referenced a number of phase [ii]{.smallcaps} trials that conformed to the inclusion criteria for the present guideline, the results of those trials were non-contributory to the final guideline recommendations. The original Sarcoma [dsg]{.smallcaps} report (found at [www.cancercare.on.ca/](www.cancercare.on.ca/)) includes the complete phase [ii]{.smallcaps} information.

5. DSG CONSENSUS PROCESS
========================

The draft guideline was circulated to the Sarcoma [dsg]{.smallcaps} for review and discussion. The group agreed that, although the available evidence indicates that the addition of ifosfamide may improve tumour response, that improvement does not translate into a survival benefit. The evidence also indicates that treatment-related toxicities are clearly increased with the addition of ifosfamide to doxorubicin-containing regimens.

6. PRACTITIONER FEEDBACK
========================

The Sarcoma [dsg]{.smallcaps} circulated the draft clinical practice guideline and systematic review to practitioners in Ontario for review and feedback.

6.1 Methods
-----------

Feedback was obtained through a mailed survey of 74 Ontario practitioners, including medical oncologists, radiation oncologists, and surgeons. The survey consisted of items evaluating the methods, results, and interpretive summary used to inform the draft recommendations and asking whether the draft recommendations should be approved as a practice guideline. Written comments were invited. The survey was mailed February 22, 2006. Follow-up reminders were sent at 2 weeks (post card) and 4 weeks (complete package mailed again). The Sarcoma [dsg]{.smallcaps} reviewed the results of the survey.

6.2 Results
-----------

From among 74 surveys mailed, 29 responses were received (39% response rate). Responses included returned completed surveys, plus telephone, fax, and e-mail responses.

Of the practitioners who responded, 9 indicated that the report was relevant to their clinical practice, and they completed the survey. One practitioner was unsure whether the guideline was relevant to personal practice, and so that practitioner's comments were not included in the results. Another indicated that the topic was relevant, but did not complete the questionnaire because of concerns that direct contact with patients was not part of current personal work. Of the respondents surveyed, most agreed (87.5%) that a need for a guideline on this topic existed, that the recommendations in the report were clear, and that the draft report should be approved as a practice guideline. All practitioners surveyed agreed with the recommendations as stated in the draft.

6.3 Summary of Written Comments and Modifications/Actions
---------------------------------------------------------

Of the 9 survey respondents, 1 provided suggestions for future document development and content. Those suggestions were noted at the [pebc]{.smallcaps}. One practitioner noted an error regarding the presentation of study results in the Discussion section. The error was corrected in the report.

7. REVIEW AND APPROVAL BY THE PEBC REPORT APPROVAL PANEL
========================================================

The final evidence-based series report was also reviewed and approved by the [pebc rap]{.smallcaps}, which consists of two members, including an oncologist with expertise in clinical and methodologic issues. Key issues raised by the [rap]{.smallcaps} were that the inclusion of the word "routine" in the recommendation created ambiguity in light of the compelling evidence demonstrating lack of benefit, and that a rationale for using response as an important and policy-determining outcome was required, as was a rationale for including phase [ii]{.smallcaps} studies, given the availability of three RCTs.

In response, the [dsg]{.smallcaps} removed the word "routine"; noted that, given the limited treatment options, response is an important outcome in this patient population; and noted that the inclusion of phase [ii]{.smallcaps} studies reflects an approach previously used (at the time the report was initially started) of including [rct]{.smallcaps}s and phase [ii]{.smallcaps} studies alike.

8. PRACTICE GUIDELINE
=====================

The current practice guideline integrates the draft practice guideline with feedback gathered by external review. This report has been approved by the Sarcoma [dsg]{.smallcaps} and the [pebc rap]{.smallcaps}.

8.1 Recommendation
------------------

In patients with metastatic [sts]{.smallcaps}, the addition of ifosfamide to standard first-line doxorubicin-containing regimens is not recommended over single-agent doxorubicin. However, in patients with symptomatic locally advanced or inoperable STS, in whom tumour response might potentially result in reduced symptomatology or render a tumour resectable, it is reasonable to use ifosfamide in combination with doxorubicin.

8.2 Qualifying Statements
-------------------------

In combination with a doxorubicin-containing regimen, the dose of ifosfamide should not exceed 7.5 g/m^2^, given as either a split bolus or a continuous infusion.

9. PRACTICE GUIDELINE DATE
==========================

Completed April 2006. Practice guidelines developed by the [pebc]{.smallcaps} are reviewed and updated regularly. Please visit the Cancer Care Ontario Web site ([www.cancercare.on.ca/](www.cancercare.on.ca/)) for the full evidence-based series report and subsequent updates.
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[^1]: Please see the Web site of Cancer Care Ontario ([www.cancercare.on.ca/](www.cancercare.on.ca/)) for a complete list of current Sarcoma Disease Site Group members.
